NICE consults on advice on two treatments for NSCLC
14th Nov 2006, 10:02 GMT
The National Institute for Health and Clinical Excellence has issued appraisal consultation documents on Tarceva (erlotinib) and Alimat (pemetrexed) for the treatment of non-small-cell lung cancer, recommending neither drug.
NICE consults on advice on two treatments for NSCLC related news:
- US national Gwendolyn Sarah Melich (R) consults with her Thai ... — Health Photos - AFP on Yahoo! News Photos
- Targeting Symptoms With Targeted Agents in NSCLC: An Expert Interview With Dr. Ezra Cohen — Medscape Pulmonary Medicine Headlines
- Nurture Mind, Body and Soul with New Treatments at the Lodge at Sonomas Raindance Spa — DBusiness News - San Francisco
- Permanent Choice Laser Hair Removal Centers Now Offering Laser Skin Treatments! — PR Leap - Advertising News Releases
- Australian Discovery Could Lead To New Leukemia Treatments — ScienceDaily Headlines: Health & Medicine
- UGA employees get sound advice on personal finances — Athens Banner Herald:UGANews
- IRS has tax advice too, and it comes free — bizjournals.com Business Services:Accounting & Consulting headlines
- Three dimensional nanowire networks and complex nanostructures of indium oxide — Journal of Applied Physics: All Topics
- Advanced NSCLC: Tailoring Treatment to the Patient — Medscape Headlines
- Parkinson's Disease Foundation Makes $200K Grant To Parkinson Study Group — Health News from Medical News Today
Latest news from OnMedica Latest News:
- Diagnosis by internet now popular and can work
- Draft NICE guidance on substance misuse available for consultation
- MDU advise on healthcare assitants giving flu vaccinations
- Drinking not recognised as mouth cancer cause
- More confusion over painkillers revealed
- New sexual health campaign for young adults
- NHS financial crisis is squeezing medical education
- World Diabetes Day is today
- NHS patients to choose hospitals through local libraries
- Patient hospital choice system needs improvement